Paul Omastiak, MD
Family Medicine · Oak Lawn, ILNPI 1821020124
Payments from drug & device makers
Across 690 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- AbbVie$2K
- Boehringer Ingelheim$1K
- GSK$1K
- Pfizer$992
- plus $5K from 31 others
What the payments were for
- Food & beverage$13,604100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 100 | $1,995 |
| AstraZeneca | 73 | $1,639 |
| AbbVie(2 entities) | 76 | $1,553 |
| Boehringer Ingelheim | 49 | $1,264 |
| GSK | 72 | $1,227 |
| Pfizer | 58 | $992 |
| Lilly USA, LLC | 46 | $787 |
| Amgen | 44 | $643 |
| Johnson & Johnson | 23 | $487 |
| Novartis | 21 | $377 |
| Sanofi-aventis U.S. LLC | 23 | $366 |
| Otsuka America Pharmaceutical, Inc. | 15 | $337 |
| Myriad Women's Health, Inc. | 1 | $228 |
| Amarin Pharma, Inc. | 14 | $224 |
| Astellas Pharma US Inc | 10 | $189 |
| Bayer | 7 | $184 |
| Merck | 6 | $125 |
| Biohaven Pharmaceuticals, Inc. | 6 | $120 |
| Abbott | 5 | $117 |
| Daiichi Sankyo Inc. | 4 | $84 |
| Ultragenyx Pharmaceutical Inc. | 3 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $72 |
| Exact Sciences | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| Sanofi Pasteur Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $53 |
| Genentech USA, Inc. | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Redhill Biopharma Inc. | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$228
- FARXIGA$115
- SYMBICORT$115
- BREZTRI AEROSPHERE$115
- BEVESPI AEROSPHERE$115
How this compares
$13,611 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $98,032 |
| FarxigaDapagliflozin Propanediol | 54 | $60,016 |
| JardianceEmpagliflozin | 37 | $57,713 |
| MounjaroTirzepatide | 21 | $29,075 |
| EliquisApixaban | 15 | $22,500 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $18,532 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,465 |
| Atorvastatin Calcium | 455 | $4,436 |
| Losartan Potassium | 198 | $2,683 |
| Levothyroxine Sodium | 171 | $2,403 |
| Amlodipine Besylate | 289 | $2,184 |
| Rosuvastatin Calcium | 127 | $2,032 |
| Pantoprazole Sodium | 98 | $1,744 |
| Metformin Hcl | 207 | $1,662 |
| Lisinopril | 139 | $1,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,995 | $98,03284 claims |
| AstraZenecaFarxiga | $1,639 | $60,01654 claims |
| Boehringer IngelheimJardiance | $1,264 | $57,71337 claims |
| Lilly USA, LLCMounjaro | $787 | $29,07521 claims |
| PfizerEliquis | $992 | $22,50015 claims |
| GSKBreo Ellipta | $1,227 | $10,46518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Oak Lawn
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.